Cargando…
Factors that influence fatigue status in patients with severe rheumatoid arthritis (RA) and good disease outcome following 6 months of TNF inhibitor therapy: a comparative analysis
The objective of the present study is to determine the factors associated with persistent fatigue in patients with severe rheumatoid arthritis (RA) and good disease response to 6 months of tumour necrosis factor inhibitor therapy. Eligible patients with either persistent (PF) or no fatigue (NF) were...
Autores principales: | Minnock, Patricia, Veale, Douglas J., Bresnihan, Barry, FitzGerald, Oliver, McKee, Gabrielle |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer London
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4624817/ https://www.ncbi.nlm.nih.gov/pubmed/26453249 http://dx.doi.org/10.1007/s10067-015-3088-6 |
Ejemplares similares
-
Oncostatin M in rheumatoid arthritis: a key cytokine acts synergistically with other proinflammatory cytokines to promote human cartilage loss
por: Fearon, U, et al.
Publicado: (2005) -
Differential Expression of NK Receptors CD94 and NKG2A by T Cells in Rheumatoid Arthritis Patients in Remission Compared to Active Disease
por: Walsh, Ceara E., et al.
Publicado: (2011) -
Acute-phase serum amyloid A production by rheumatoid arthritis
synovial tissue
por: O'Hara, Rosemary, et al.
Publicado: (2000) -
Apolipoprotein A-I infiltration in rheumatoid arthritis synovial tissue: a control mechanism of cytokine production?
por: Bresnihan, Barry, et al.
Publicado: (2004) -
Human rheumatoid arthritis tissue production of IL-17A drives matrix and cartilage degradation: synergy with tumour necrosis factor-α, Oncostatin M and response to biologic therapies
por: Moran, Ellen M, et al.
Publicado: (2009)